PubMed Jastreboff, A.M., Kaplan, L.M., Fras, J.P., Wu, Q., Du, Y., Gurbuz, S., Coskun, T., Haupt, A., Milicevic, Z., & Hartman, M.L
For legitimate side-effect information, see our GLP-1 side effects guide
It has to clear a regulatory route before it can move from research into ordinary clinical use
Marketing and Distribution Costs Novo Nordisk spends substantial amounts on marketing to healthcare providers and consumers
Understanding the potential side effects and how to manage them can empower patients, making them active participants in their treatment journey
Magnitude of slowing gastric emptying by glucagon-like peptide-1 receptor agonists determines the amelioration of postprandial glucose excursion in Japanese patients with type 2 diabetes